Ironwood Pharmaceuticals (IRWD) Receivables (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Receivables across 17 years of filings, most recently posting $112.7 million for Q2 2026.

• In Q2 2026, Receivables rose 30.78% year-over-year to $112.7 million; the TTM figure through Jun 2026 stood at $112.7 million (up 30.78% YoY), while the FY2025 annual figure was $46.7 million, down 42.92% from the prior year.
• Receivables came in at $112.7 million for Q2 2026 at Ironwood Pharmaceuticals, up from $105.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $131.0 million in Q3 2022 to a low of $39.8 million in Q1 2025.
• Average Receivables over 5 years is $99.2 million, with a median of $114.2 million recorded in 2023.
• Year-over-year, Receivables tumbled 51.17% in 2024 and surged 165.93% in 2026.
• Over 5 years, Receivables stood at $130.0 million in 2022, then decreased by 0.69% to $129.1 million in 2023, then slumped by 36.56% to $81.9 million in 2024, then slumped by 42.98% to $46.7 million in 2025, then jumped by 141.4% to $112.7 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $112.7 million in Q2 2026, $105.8 million in Q1 2026, and $46.7 million in Q4 2025.